Guangzhou Vesber Biotechnology Co., Ltd. is a national high-tech enterprise specializing in R&D, production, and sales of innovative ophthalmic products. The company is headquartered in the core area of the Guangdong-Hong Kong-Macao Greater Bay Area, Guangdong Medical Valley Industrial Park, Nansha District. With a total of six floors in a detached building, the company, covering an area of 5,023 square meters, is equipped with a 100,000-grade clean workshop, Vesber Research Institute, Vesber Engineering Center, Clinical Training Center, etc. Up to now, Vesber has gained investments from state-owned enterprises such as Guangdong Technology Financial Group Co., Ltd., Guangzhou GET Investment Holdings Co., Ltd., GEM-listed company Ovctek China Inc., Guangdong Xiangsanze Pharmaceutical Venture Capital Investment Enterprise, Leishitaihe Equity Investment Fund Management Partnership, and other enterprises. 

Relying on the powerful R&D platform of Zhongshan Ophthalmic Eye Center of Sun Yat-sen University, Vesber researches and develops innovative ophthalmic products with a rigorous,  scientific and responsible attitude. The main products are the Foldable Capsular Vitreous Body (FCVB), the Foldable Capsular Buckle (FCB), Silicone Scleral Buckle (SSB), and High Myopia Scleral Reinforcement System (HM), etc. 

FCVB, as the representative product, is the first innovative product to save the eyeball worldwide, which can accurately stimulate the vitreous body of the human eye. Since it was launched in 2017, more than 200 ophthalmologists have carried out FCVB implantation surgery in 150 hospitals in 24 provinces. It has served more than 5,000 patients, including the army, children, and national minorities. Additionally, it has been selected as one of the 2018 Medical Device Innovation Catalogue of the Ministry of Science and Technology of the People's Republic of China. In the review of the 40th Anniversary of the reform and opening-up, it was cited as a typical example of how “Made in China” changed into “Created in China” by the National Medical Products Administration

FCB is an innovative “ultra-minimally invasive” extra-ocular approach for treating rhegmatogenous retinal detachment (RRD). The multi-center clinical trials of FCB initiated in July 2019 in China. Twenty-two ophthalmology hospitals participated in it and served nearly 200 patients. And the multi-center clinical trials have been concluded at the end of October in 2022 in China. With its launch, FCB will bring new hopes to the patients who suffered from RRD. 

HM（High Myopia Scleral Reinforcement System） is independently developed by Vesber for the purpose of delaying the worsening of myopia and treating posterior scleral staphylomas and retinoschisis caused by high myopia, etc. And now, the multi-center clinical trials of HM are underway in several hospitals in China.

Since its establishment in 2007, Vesber has received a series of government funds such as the 863 Program, the National Science and Technology Pillar Program during the 12th Five-Year Plan Period, the SME Innovation Fund, the Science and Technology Planning Project of Guangdong Province, etc. The company owns 27 patents from the US, Australia, China and other countries.

In 2013, FCVB was awarded as one of the world’s four advances in retinal detachment surgery. In 2015, FCVB was awarded as the “Top 10 Achievements of China’s Ophthalmology in 2015” by the Chinese Medical Association. In 2017, Vesber was awarded as one of “the first batch of high and new technology enterprises”of Guangdong Province. In 2019, FCVB was awarded “High-Tech Products in Guangdong Province.” In 2019, Vesber won the title of “Guangdong Province Annual Quality Credit Class A Medical Device Manufacturer.” In 2020, Vesber won the “National High and New Technology Enterprise” title again. In 2020, FCVB was listed in the grade 4 surgical catalog in the performance appraisal of tertiary public hospitals. In 2021, FCVB was awarded as a “famous high and new technical product” in Guangdong province. Additionally, FCVB had also been  featured by CCTV1 and Xinhua News Agency in 2021. And in 2021, Vesber again won the “Guangdong Province Annual Quality Credit Class A Medical Device Manufacturer” title.In 2023, FCVB was awarded the first prize in the Medical Science and Technology Award. In 2023, FCVB was selected as one of the top 10 cases of transformation of scientific and technological achievements in Nansha district. In 2023, FCVB was awarded the Special Prize of Tianjin Scientific and technological progress. In 2023, FCVB won the 10th Guangdong Provincial Patent Award.